Clinical trials: High Risk Prostate Cancer
Prostate Cancer
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
This is a phase I neoadjuvant gene therapy followed by prostatectomy, open-label, dose-escalation trial for prostate cancer patients with high risk of local recurrence after radical prostatectomy.
- Trial name
- NCT01197209
- Testing
- Ad-REIC/Dkk-3
- Where
- United States
- Sponsor
- Momotaro-Gene Inc.
Prostate Adenocarcinoma
Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer
The present study is a phase III randomized and multicentric trial evaluating the potential additional impact effect of two years adjuvant androgen deprivation when combined with neoadjuvant (4 months) and high-dose (76 Gy)…
- Trial name
- AADLPC (NCT02175212)
- Testing
- Short term androgen deprivation, Long term androgen deprivation
- Where
- Spain
- Volunteers
- 362 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Prostate Cancer
High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)
The purpose of this study is to find out the effects (good and bad) of using newer technologies that allow very precise delivery of radiation.
- Trial name
- SIB (NCT02177292)
- Testing
- Radiation Therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medical College of Wisconsin
Prostatic Intraepithelial Neoplasia
Broccoli, Peas and PIN
This is a parallel human intervention trial to determine to what extent a dietary intervention of broccoli or peas can change the expression (switching on or off) of genes in prostate tissue in men diagnosed with high-grade…
- Trial name
- NCT00535977
- Testing
- Broccoli, Peas
- Volunteers
- 22 people
- Sponsor
- Quadram Institute Bioscience
Prostate Cancer
EMBRACE1: Prostate Biorepository
The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for…
- Trial name
- NCT01499381
- Where
- United States
- Volunteers
- 1,290 people
- Sponsor
- Caris Science, Inc.
Prostatic Neoplasms
Men at High Genetic Risk for Prostate Cancer
Background: Research studies have shown that genetic changes and family history may increase a man s risk for prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated…
- Trial name
- NCT03805919
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Non-Invasive Biomarkers in Prostate Cancer Disease Management
This study is an observational retrospective/ prospective study with diagnosed low/intermediate risk (no-surgery) \& high risk (surgery) prostate cancer that are eligible and willing to undergo standard of care (SOC) assessment…
- Trial name
- NCT06144619
- Testing
- Genomic and Histological Evaluation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
High-risk Prostate Cancer, Prostate Cancer
Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+ valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy, external beam radiotherapy, and prostatectomy in…
- Trial name
- NCT03541928
- Testing
- HSV-Tk, Valacyclovir, Bicalutamide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Methodist Hospital Research Institute
Prostate Cancer (Adenocarcinoma)
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
- Trial name
- DE-CART (NCT07219303)
- Testing
- adaptive stereotactic body radiation therapy (SBRT) with a SIB
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce…
- Trial name
- NCT03436654
- Testing
- Apalutamide, Abiraterone Acetate, Prednisone
- Where
- 11 sites in United States
- Volunteers
- 102 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly…
- Trial name
- NCT04989946
- Testing
- Degarelix, pTVG-AR, Nivolumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Wisconsin, Madison
Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer.
- Conditions
- Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Trial name
- NCT06129851
- Testing
- Biospecimen Collection, Bone Scan, Brachytherapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer
Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment
TITLE Timing of HDR brachytherapy with EBRT in intermediate and high risk localised Prostate CAncer patients and its effects on Toxicity and Quality of life - randomised feasibility trial.
- Trial name
- THEPCA (NCT02618161)
- Testing
- HDR Brachytherapy, External beam Radiotherapy
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Mid and South Essex NHS Foundation Trust